This pathway is activated by Wnt/GSK-3β independently of β-catenin [30] and is considered another anti-oncogenic effect of GSK-3β in PDAC as mTOR is a major pro-cancer effector in PDAC [31,32]. This evidence concerns the gene MTOR and cancer.